Bayer receives FDA approval for long-term contraceptive

Bayer receives FDA approval for long-term contraceptive
Bayer HealthCare has received approval from the U.S. Food and Drug Administration for its new low-dose levonorgestrel-releasing intrauterine system called Skyla, according a Jan. 10 news release issued by the company.

(HealthDay)—Bayer HealthCare has received approval from the U.S. Food and Drug Administration for its new low-dose levonorgestrel-releasing intrauterine system (IUS) called Skyla, according a Jan. 10 news release issued by the company.

Bayer describes Skyla as a small, flexible plastic T-shaped device containing 13.5 mg of the hormone levonorgestrel. The 28 mm × 30 mm Skyla T-body is put in place through a 3.8 mm-diameter tube. A slow, low dose of is locally released in the uterus, with only small amounts of the hormone entering the bloodstream. The IUS prevents pregnancy for up to three years.

The regulatory approval of Skyla was based on data from a multi-national, randomized open-label Phase 3 trial of 2,884 women (aged 18 to 35 years), in which 1,432 women received Skyla. The IUS was 99 percent effective in preventing pregnancy and was well tolerated with no unexpected . There were low incidences of ectopic pregnancy, , expulsion of the device from the uterus, and uterine perforation.

"The approval of Skyla in the United States highlights Bayer's continued commitment to drive innovation and empower women with a variety of birth control options at different reproductive stages of their lives," Kemal Malik, M.D., Bayer's head of global development, said in a statement.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

ACOG: Intrauterine device insertion linked to weight loss

May 07, 2012

(HealthDay) -- Women who undergo postpartum or interval insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) or Copper T 380A (CU-T) intrauterine devices experience weight loss in the two years ...

'Morning After Pill' Works up to 5 Days After Sex

Feb 22, 2010

(PhysOrg.com) -- A team of researchers from the United States and Europe has published new evidence supporting the use of ulipristal acetate as an effective alternative to levonorgestrel (marketed as Plan B®) for emergency ...

FDA ties newer birth control drugs to blood clots

Oct 27, 2011

(AP) -- Safety concerns with the popular birth control pill Yaz increased Thursday as federal health scientists reported that the Bayer drug and other newer birth control treatments appear to increase the risk of dangerous ...

Consider IUDs for contraception, other conditions

Apr 13, 2012

Researchers at the University of Cincinnati (UC) have found that intrauterine devices (IUDs) containing progesterone are a safe and effective means of birth control and support its use as a treatment option for medical conditions ...

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

7 hours ago

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

11 hours ago

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

21 hours ago

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

Interpol call for roadmap to tackle fake drugs

Nov 19, 2014

Interpol on Wednesday called for a greater global response to pharmaceutical crime as it warned criminal gangs were capitalising on weaknesses in legislation and border controls.

Empagliflozin in type 2 diabetes: Added benefit not proven

Nov 19, 2014

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.